This segment focuses on the research, development, and commercialization of therapeutics for the treatment of pruritus (itching). The primary focus is on KORSUVA (difelikefalin), a kappa opioid receptor agonist. Research and development activities include clinical trials for various indications, including pruritus associated with chronic kidney disease (CKD) in hemodialysis patients, atopic dermatitis, non-dialysis-dependent chronic kidney disease (NDD-CKD), and chronic liver disease (CLD). Technologies employed include targeting the peripheral nervous system and immune cells. The patient impact is significant, as pruritus can severely impact quality of life. Market positioning involves partnerships with companies like Vifor Pharma for commercialization. Future opportunities include expanding the indications for KORSUVA and developing oral formulations. Regulatory aspects involve seeking FDA approval and navigating clinical trial phases. Collaborations with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation are in place for development and commercialization in Japan and South Korea, respectively.

This segment is dedicated to the development of therapeutics for pain management, leveraging the company's expertise in targeting the kappa opioid receptor. Research and development efforts are focused on identifying and developing novel compounds that can effectively alleviate pain. The company utilizes advanced methodologies in drug discovery and clinical trials to evaluate the safety and efficacy of its product candidates. The therapeutic areas covered include acute and chronic pain conditions. The patient impact is aimed at providing relief and improving the quality of life for individuals suffering from various pain syndromes. Market positioning involves strategic partnerships and collaborations to ensure effective commercialization and market access. Future opportunities include expanding the pipeline with new pain management therapies and exploring different delivery methods. Regulatory aspects involve obtaining necessary approvals from regulatory bodies such as the FDA. The company is actively seeking partnerships to expand its reach and accelerate the development of its pain management portfolio.